The US Food and Drug Administration Approves deucravacitinib (Sotyktu) for Oral Treatment of Moderate-to-Severe Plaque Psoriasis in Adults

The FDA has approved a new treatment for moderate-to-severe plaque psoriasis. Manufactured by Bristol Myers Squibb, deucravacitinib (Sotyktu) is an oral allosteric tyrosine kinase 2 (TYK2) inhibitor with potential to become a new standard for care.

Related Skin Conditions